Docoh
Loading...

MCK Mckesson

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, its employees work every day to innovate and deliver opportunities that make our customers and partners more successful - all for the better health of patients. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly.

Company profile

Ticker
MCK
Exchange
CEO
Brian Tyler
Employees
Incorporated
Location
Fiscal year end
Former names
MCKESSON HBOC INC
SEC CIK
IRS number
943207296

MCK stock data

(
)

Calendar

2 Feb 21
13 Apr 21
31 Mar 22
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 20 Mar 19 Mar 18 Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Mckesson earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.73B 3.73B 3.73B 3.73B 3.73B 3.73B
Cash burn (monthly) (positive/no burn) (positive/no burn) 2.45B 402.42M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 8.48B 1.39B n/a n/a
Cash remaining n/a n/a -4.75B 2.34B n/a n/a
Runway (months of cash) n/a n/a -1.9 5.8 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Mar 21 Tyler Brian S. Common Stock Sell Dispose S No Yes 186.66 5,511 1.03M 18,990
15 Mar 21 Tyler Brian S. Common Stock Option exercise Aquire M No Yes 183.37 5,511 1.01M 24,501
15 Mar 21 Tyler Brian S. Employee Stock Option (right-to-buy) Common Stock Option exercise Dispose M No No 183.37 5,511 1.01M 5,511
16 Feb 21 Tyler Brian S. Common Stock Sell Dispose S No Yes 183.38 5,510 1.01M 18,990
16 Feb 21 Tyler Brian S. Common Stock Option exercise Aquire M No Yes 183.37 5,510 1.01M 24,500
16 Feb 21 Tyler Brian S. Employee Stock Option (right-to-buy) Common Stock Option exercise Dispose M No No 183.37 5,510 1.01M 11,022
7 Feb 21 Flores Nancy Common Stock Payment of exercise Dispose F No No 183.06 1,526 279.35K 4,055.713
7 Feb 21 Flores Nancy Common Stock Option exercise Aquire M No No 0 5,438 0 5,438
7 Feb 21 Flores Nancy RSU Common Stock Option exercise Dispose M No No 0 5,438 0 5,438
15 Jan 21 Tyler Brian S. Common Stock Sell Dispose S No Yes 184.733 2,500 461.83K 18,990

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

86.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 924 846 +9.2%
Opened positions 159 84 +89.3%
Closed positions 81 67 +20.9%
Increased positions 301 269 +11.9%
Reduced positions 315 329 -4.3%
13F shares
Current Prev Q Change
Total value 23.88B 20.71B +15.3%
Total shares 137.31M 137.98M -0.5%
Total puts 1.54M 781.4K +96.6%
Total calls 1.24M 884.5K +40.7%
Total put/call ratio 1.2 0.9 +39.7%
Largest owners
Shares Value Change
Vanguard 16.25M $2.83B -1.5%
BLK Blackrock 13.97M $2.43B -3.8%
STT State Street 7.36M $1.28B -2.8%
JPM JPMorgan Chase & Co. 7.2M $1.25B +27.7%
Massachusetts Financial Services 5.91M $1.03B -0.0%
FMR 3.6M $625.42M -5.6%
IVZ Invesco 3.5M $609.38M -11.4%
PZN Pzena Investment Management 3.09M $537.31M -7.4%
Boston Partners 2.84M $493.71M -15.9%
Geode Capital Management 2.81M $488.2M +0.6%
Largest transactions
Shares Bought/sold Change
Norges Bank 1.83M +1.83M NEW
Baupost 0 -1.67M EXIT
JPM JPMorgan Chase & Co. 7.2M +1.56M +27.7%
Wellington Management 427.22K -1.16M -73.1%
Capital Ventures International 865.16K +865.16K NEW
PKW Parkwood 0 -714.8K EXIT
Ci Investments 1.28M -592.91K -31.7%
BLK Blackrock 13.97M -545.41K -3.8%
Boston Partners 2.84M -536.95K -15.9%
Ajo 56.4K -503.06K -89.9%

Financial report summary

?
Risks
  • We experience costly and disruptive legal disputes.
  • We might experience losses not covered by insurance.
  • We experience costly legal disputes, government actions and adverse publicity regarding our role in distributing controlled substances such as opioids.
  • We might experience increased costs to distribute controlled substances such as opioids.
  • We are subject to extensive, complex and challenging healthcare and other laws.
  • We are subject to extensive and frequently changing local, state and federal laws and regulations relating to healthcare fraud, waste and abuse.
  • We might lose our ability to purchase, compound, store or distribute pharmaceuticals and controlled substances.
  • Pedigree tracking laws increase our compliance burden and our pharmaceutical distribution costs.
  • Privacy and data protection laws increase our compliance burden.
  • Anti-bribery and anti-corruption laws increase our compliance burden.
  • We might record significant charges from impairment to goodwill, intangibles and other assets or investments.
  • We experience cybersecurity incidents and might experience significant computer system compromises or data breaches.
  • We might experience significant problems with information systems or networks.
  • Our products or services might not conform to specifications or perform as we intend.
  • We might be impeded in providing customers online services and data access.
  • We might not realize expected benefits from business process initiatives.
  • We might be unable to successfully complete or integrate acquisitions or other business combinations.
  • We might be adversely impacted by delays or other difficulties with divestitures.
  • We might not realize the expected tax treatment from our split-off of Change Healthcare.
  • We might be adversely impacted by outsourcing or similar third-party relationships.
  • We may be unsuccessful in retail pharmacy operations or maintaining profitability.
  • We might be harmed by large customer purchase reductions, payment defaults or contract non-renewal.
  • Our contracts with government entities involve future funding and compliance risks.
  • We might be harmed by changes in our relationships or contracts with suppliers.
  • We might infringe intellectual property rights or our intellectual property protections might be inadequate.
  • We might be unable to successfully recruit and retain qualified employees.
  • We might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
  • We might be adversely impacted by competition and industry consolidation.
  • We might be adversely impacted by changes or disruptions in product supply.
  • We might be adversely impacted as a result of our distribution of generic pharmaceuticals.
  • We might be adversely impacted by an economic slowdown or recession.
  • Disruption or other changes in capital and credit markets might impede access to credit and increase borrowing costs for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers.
  • We may have difficulties in sourcing or selling products due to a variety of causes.
  • We might be adversely impacted by tax legislation or challenges to our tax positions.
  • We might be adversely impacted by the Brexit withdrawal of the United Kingdom from the European Union.
  • We might be adversely impacted by fluctuations in foreign currency exchange rates.
  • We might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
  • We might be adversely impacted by changes in accounting standards.
Management Discussion
  • U.S. Pharmaceutical and Specialty Solutions revenues for the year ended March 31, 2020 increased 9% compared to the prior year primarily due to market growth, including branded pharmaceutical price increases, higher volumes from retail national account customers and growth in specialty pharmaceuticals, partially offset by brand to generic drug conversions.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absent, accessible, agent, Alabama, allegedly, appraisal, binding, Bundesgerichtshof, BVI, CA, Celesio, Chase, Citibank, clothing, compressed, conclusion, confirmed, Davidson, decide, dedicated, default, defense, deficit, delivery, derecognized, diluent, disposition, distinguish, downgrade, Dragonfly, dry, economy, enabled, environmental, EUA, exacerbated, facial, Fargo, FDA, fell, Fitch, Food, gear, Germany, GmbH, Goldman, heard, HSBC, ice, incorrectly, indenture, inherent, investee, JPMorgan, Kempner, KGaA, kit, kitting, lesser, letter, Master, member, merge, minimize, Moderna, ModernaTX, Moody, mount, nil, Oberlandesgericht, occurrence, online, Ordinance, original, overturned, paused, petition, Pfizer, physical, PLC, Polygon, Poor, PPE, presence, proceeding, rank, refrigerated, Regional, rehearing, rejected, remediate, resale, role, shipped, Standard, storage, Stuttgart, substance, takeover, thereto, undertaken, unpaid, unprecedented, upper, USA, viral, waiving, warrant, WBA, Worth, written
Removed: approval, asserted, breach, complex, complexity, duty, ending, expressly, fall, false, fiduciary, fix, flat, Henry, inflation, intending, Jean, nominal, novelty, operation, point, purported, qui, removing, represented, semiannually, shift, successful, Superior, tam, Tyler, viable, waste, wrongdoing